Juvenile idiopathic arthritis

Berent Prakken, Salvatore Albani, Alberto Martini

Research output: Contribution to journalArticle

333 Citations (Scopus)

Abstract

Juvenile idiopathic arthritis is a heterogeneous group of diseases characterised by arthritis of unknown origin with onset before age of 16 years. Pivotal studies in the past 5 years have led to substantial progress in various areas, ranging from disease classification to new treatments. Gene expression profiling studies have identified different immune mechanisms in distinct subtypes of the disease, and can help to redefine disease classification criteria. Moreover, immunological studies have shown that systemic juvenile idiopathic arthritis is an acquired autoinflammatory disease, and have led to successful studies of both interleukin-1 and interleukin-6 blockade. In other forms of the disease, synovial inflammation is the consequence of a disturbed balance between proinflammatory effector cells (such as T-helper-17 cells), and anti-inflammatory regulatory cells (such as FOXP3-positive regulatory T cells). Moreover, specific soluble biomarkers (S100 proteins) can guide individual treatment. Altogether these new developments in genetics, immunology, and imaging are instrumental to better define, classify, and treat patients with juvenile idiopathic arthritis.

Original languageEnglish
Pages (from-to)2138-2149
Number of pages12
JournalLancet
Volume377
Issue number9783
DOIs
Publication statusPublished - Jun 18 2011

Fingerprint

Juvenile Arthritis
Th17 Cells
S100 Proteins
Gene Expression Profiling
Regulatory T-Lymphocytes
Allergy and Immunology
Interleukin-1
Age of Onset
Arthritis
Interleukin-6
Anti-Inflammatory Agents
Biomarkers
Inflammation
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Juvenile idiopathic arthritis. / Prakken, Berent; Albani, Salvatore; Martini, Alberto.

In: Lancet, Vol. 377, No. 9783, 18.06.2011, p. 2138-2149.

Research output: Contribution to journalArticle

Prakken, B, Albani, S & Martini, A 2011, 'Juvenile idiopathic arthritis', Lancet, vol. 377, no. 9783, pp. 2138-2149. https://doi.org/10.1016/S0140-6736(11)60244-4
Prakken, Berent ; Albani, Salvatore ; Martini, Alberto. / Juvenile idiopathic arthritis. In: Lancet. 2011 ; Vol. 377, No. 9783. pp. 2138-2149.
@article{c293015dd2ec48bd93268308408c5aad,
title = "Juvenile idiopathic arthritis",
abstract = "Juvenile idiopathic arthritis is a heterogeneous group of diseases characterised by arthritis of unknown origin with onset before age of 16 years. Pivotal studies in the past 5 years have led to substantial progress in various areas, ranging from disease classification to new treatments. Gene expression profiling studies have identified different immune mechanisms in distinct subtypes of the disease, and can help to redefine disease classification criteria. Moreover, immunological studies have shown that systemic juvenile idiopathic arthritis is an acquired autoinflammatory disease, and have led to successful studies of both interleukin-1 and interleukin-6 blockade. In other forms of the disease, synovial inflammation is the consequence of a disturbed balance between proinflammatory effector cells (such as T-helper-17 cells), and anti-inflammatory regulatory cells (such as FOXP3-positive regulatory T cells). Moreover, specific soluble biomarkers (S100 proteins) can guide individual treatment. Altogether these new developments in genetics, immunology, and imaging are instrumental to better define, classify, and treat patients with juvenile idiopathic arthritis.",
author = "Berent Prakken and Salvatore Albani and Alberto Martini",
year = "2011",
month = "6",
day = "18",
doi = "10.1016/S0140-6736(11)60244-4",
language = "English",
volume = "377",
pages = "2138--2149",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Lancet Publishing Group",
number = "9783",

}

TY - JOUR

T1 - Juvenile idiopathic arthritis

AU - Prakken, Berent

AU - Albani, Salvatore

AU - Martini, Alberto

PY - 2011/6/18

Y1 - 2011/6/18

N2 - Juvenile idiopathic arthritis is a heterogeneous group of diseases characterised by arthritis of unknown origin with onset before age of 16 years. Pivotal studies in the past 5 years have led to substantial progress in various areas, ranging from disease classification to new treatments. Gene expression profiling studies have identified different immune mechanisms in distinct subtypes of the disease, and can help to redefine disease classification criteria. Moreover, immunological studies have shown that systemic juvenile idiopathic arthritis is an acquired autoinflammatory disease, and have led to successful studies of both interleukin-1 and interleukin-6 blockade. In other forms of the disease, synovial inflammation is the consequence of a disturbed balance between proinflammatory effector cells (such as T-helper-17 cells), and anti-inflammatory regulatory cells (such as FOXP3-positive regulatory T cells). Moreover, specific soluble biomarkers (S100 proteins) can guide individual treatment. Altogether these new developments in genetics, immunology, and imaging are instrumental to better define, classify, and treat patients with juvenile idiopathic arthritis.

AB - Juvenile idiopathic arthritis is a heterogeneous group of diseases characterised by arthritis of unknown origin with onset before age of 16 years. Pivotal studies in the past 5 years have led to substantial progress in various areas, ranging from disease classification to new treatments. Gene expression profiling studies have identified different immune mechanisms in distinct subtypes of the disease, and can help to redefine disease classification criteria. Moreover, immunological studies have shown that systemic juvenile idiopathic arthritis is an acquired autoinflammatory disease, and have led to successful studies of both interleukin-1 and interleukin-6 blockade. In other forms of the disease, synovial inflammation is the consequence of a disturbed balance between proinflammatory effector cells (such as T-helper-17 cells), and anti-inflammatory regulatory cells (such as FOXP3-positive regulatory T cells). Moreover, specific soluble biomarkers (S100 proteins) can guide individual treatment. Altogether these new developments in genetics, immunology, and imaging are instrumental to better define, classify, and treat patients with juvenile idiopathic arthritis.

UR - http://www.scopus.com/inward/record.url?scp=79959370461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959370461&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(11)60244-4

DO - 10.1016/S0140-6736(11)60244-4

M3 - Article

VL - 377

SP - 2138

EP - 2149

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9783

ER -